Citadel Advisors’s Tyra Biosciences TYRA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$682K Buy
+17,800
New +$576K ﹤0.01% 8545
2025
Q2
Sell
-5,400
Closed -$50.2K 15178
2025
Q1
$50.2K Sell
5,400
-600
-10% -$7.76K ﹤0.01% 12311
2024
Q4
$83.4K Buy
6,000
+4,900
+445% +$88.9K ﹤0.01% 11734
2024
Q3
$25.9K Buy
+1,100
New +$23.1K ﹤0.01% 12570
2024
Q2
Sell
-3,700
Closed -$60.7K 15443
2024
Q1
$60.7K Buy
+3,700
New +$60.7K ﹤0.01% 11984
2023
Q1
Sell
-1,000
Closed -$7.6K 15537
2022
Q4
$7.6K Buy
+1,000
New +$7.07K ﹤0.01% 13815

Other funds holding TYRA

Citadel Advisors's TYRA Position: Q1 2026 in Review

Citadel Advisors opened a new position in Tyra Biosciences (TYRA) in Q1 2026: 15,396 shares worth $590K. The stake represents ﹤0.01% of the portfolio and ranks #8899 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in TYRA as recently as Q3 2025.

Citadel Advisors first reported a position in TYRA in Q4 2021 and has held it in 12 quarters since. The position peaked at $2.07M in Q2 2025. 164 funds tracked by Wall St. Rank hold TYRA as of Q1 2026.

  • Citadel Advisors held 15,396 shares of Tyra Biosciences worth $590K as of Q1 2026.
  • Tyra Biosciences was a new Citadel Advisors position in Q1 2026.
  • Tyra Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #8899 holding.
  • Citadel Advisors first reported a position in Tyra Biosciences in Q4 2021 and has held it in 12 quarters since.
  • Citadel Advisors's Tyra Biosciences position peaked at $2.07M in Q2 2025.
  • 164 funds tracked by Wall St. Rank held Tyra Biosciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.